NN8022-4246 In market utilisation of liraglutide used for weight management in the UK: a study in the CPRD primary care database

Study identification

• EU PAS number:
  EUPAS23369
• Study ID:
  50321
• Official title and acronym:
  NN8022-4246 In market utilisation of liraglutide used for weight management in the UK: a study in the CPRD primary care database
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  This study is conducted in Europe. The aim of this study is to investigate usage of liraglutide for weight management in clinical practice using the CPRD (Clinical Practice Research Datalink) primary care database.
• Study status:
  Finalised

Research institutions and networks

Institutions

Novo Nordisk

Study timelines

Date when funding contract was signed

Actual: 26/02/2015

Study start date

Planned: 20/04/2018

Actual: 13/04/2018

Date of final study report

Planned: 31/07/2023

Actual: 31/07/2023

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Novo Nordisk A/S

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)

Other study registration identification numbers and links

UTN: U1111-1185-3276,NCT: NCT03479762